Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@article{Marso2016SemaglutideAC,
  title={Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.},
  author={Steven P. Marso and Stephen C Bain and Agostino Consoli and Freddy Goldberg Eliaschewitz and Esteban J{\'o}dar and Lawrence A Leiter and Ildiko Lingvay and Julio Rosenstock and Jochen Seufert and Mark L Warren and Vincent Woo and Oluf K H Hansen and Anders Gaarsdal Holst and Jonas Pettersson and Tina Vilsb\oll},
  journal={The New England journal of medicine},
  year={2016},
  volume={375 19},
  pages={1834-1844}
}
BACKGROUND Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown. METHODS We randomly assigned 3297 patients with type 2 diabetes who were on a standard-care regimen to receive once-weekly semaglutide (0.5 mg… CONTINUE READING
Highly Influential
This paper has highly influenced 27 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS